Target intelligence / Profile preview

F-box protein 48 (FBXO48)

Target
FBXO48
Molecular classification
Ubiquitin E3 ligase subunit, F-box protein, SCF (Skp1–Cullin1–F-box) complex component
01

Overview

FBXO48 is a member of the F-box protein family and functions as an E3 ubiquitin ligase subunit within the SCF complex. Its primary known role is to recognize and target phosphorylated AMPKα for polyubiquitylation and subsequent proteasomal degradation. This positions FBXO48 as a negative regulator of cellular energy homeostasis, controlling the cellular signaling cascade that governs mitochondrial fission, autophagy, and insulin sensitivity. Inhibition of FBXO48, for example with small molecules such as BC1618, can prevent pAMPKα degradation, enhance AMPK-mediated metabolic effects, and improve hepatic insulin sensitivity, suggesting promise for metabolic disease therapy. FBXO48 is genomically localized to 2p13.3, a region connected to Parkinson's disease in genetic studies, though direct disease–causing mutations have not been established.

Other names
F-box only protein 48FBXO48FBX48F-box protein 48
02

Mechanism of action

Inhibition of FBXO48 prevents ubiquitylation and degradation of pAMPKα, resulting in maintained AMPK signaling and downstream metabolic effects

03

Biological functions

Protein ubiquitination (specifically, polyubiquitination of phosphorylated AMPKα for proteasomal degradation)Regulation of cellular energy metabolismNegative regulation of AMPK signalingModulation of mitochondrial fissionFacilitation of autophagy
04

Disease associations

Metabolic syndrome (including hepatic insulin resistance and obesity)Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH)Potential neurodegenerative association (Parkinson's disease locus)
05

Safety considerations

Off-target effects of small molecule inhibitors remain to be further characterized; no major toxicity reported with BC1618 in vitro, but broader safety data are lackingAs a component of proteostatic regulation, unwanted modulation could disturb cellular protein balance in unpredictable ways.
06

Interacting drugs

BC1618
07

Biomarkers

FBXO48 protein expression (elevated in liver samples from NASH patients; may correlate with metabolic dysfunction)pAMPKα protein levels (as a measure of pathway activity for patient stratification or pharmacodynamic monitoring)

Beyond the preview

Go deeper on F-box protein 48 (FBXO48).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box protein 48 (FBXO48).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call